Inclusion Criteria:

- Histologically confirmed digestive or breast cancer that is metastatic or
unresectable, for which no curative measures are possible, and chemorefractory to all
known medications in the respective fields.

- Age ≥ 18 years.

- Life expectancy of greater than 12 weeks.

- ECOG (Eastern Cooperative Oncology Group) performance status ≤ 1.

- Normal organ and marrow function as defined below:

- Leukocytes > 3,000/microLiter (mcL)

- Hb>10g/mcL

- Absolute neutrophil count > 1,500/mcL

- Platelets > 100,000/mcL

- Total bilirubin within 2 × institutional upper limit of normal

- AST (aspartate amino transferase)/ALT (alanine amino transferase)/ALKP (Alkaline
Phosphatase) levels < 5 × institutional upper limit of normal for liver
metastases, < 2.5 ULN (Upper Limit of Normal) in case of no liver metastases

- Creatinine within 2 × institutional upper limit of normal or creatinine
clearance > 35 mL/min

- Women of childbearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control, abstinence) prior to study entry and
for the duration of study participation. Should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately.

- Signed written informed consent (approved by an Independent Ethics Committee (IEC))
obtained prior to any study specific baseline procedures.

Exclusion Criteria:

- Patients with malabsorption or dysfunctional GI tract.

- Participants who have had chemotherapy or radiotherapy (except limited radiotherapy
for bone metastasis for instance) within 4 weeks prior to entering the study or those
who have not recovered from adverse events due to agents administered more than 4
weeks earlier.

- Participants should not receive any other experimental agents.

- Participants with known brain metastases should be excluded from this clinical trial
because of their poor prognosis and because they often develop progressive neurologic
dysfunction that would confound the evaluation of neurologic and other adverse
events.

- Bleeding diathesis, history of cardiovascular ischemic disease or cerebrovascular
incident within the last six months.

- Major surgery within 6 weeks.

- Uncontrolled concurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women, lactation or refusal to use adequate contraceptive measures (hormonal
or barrier method of birth control, abstinence).